William Fairey - Jun 5, 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Jun 5, 2024
Transactions value $
$0
Form type
4
Date filed
6/7/2024, 06:19 PM
Previous filing
Apr 22, 2024
Next filing
Aug 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Award $0 +8.78K $0.00 8.78K Jun 5, 2024 Common Stock 8.78K $26.30 Direct F1
transaction MIRM Restricted Stock Units Award $0 +5.7K $0.00 5.7K Jun 5, 2024 Common Stock 5.7K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.